Kincell Bio, a technology-forward CDMO focused on cell therapies, has launched having received $36 million in new funding led by Kineticos Ventures.
Kincell is a spinout of Inceptor Bio’s CMC, manufacturing and quality organizations formed to accelerate innovator research and clinical trials. Kincell has a facility and a fully staffed team based at its Gainesville site, with plans to grow in Gainesville, as well as in additional key markets, such as Research Triangle Park, Boston and other customer locations.
